Manufacturer of Controlled Substances; Notice of Application, 64677 [E7-22505]
Download as PDF
<![CDATA[
64677
Federal Register / Vol. 72, No. 221 / Friday, November 16, 2007 / Notices
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
Drug
Schedule
N-Ethylamphetamine (1475) ........................................................................................................................................................................
Tetrahydrocannabinols (7370) .....................................................................................................................................................................
2,5-Dimethoxyamphetamine (7396) ............................................................................................................................................................
3,4-Methylenedioxyamphetamine (7400) ....................................................................................................................................................
4-Methoxyamphetamine (7411) ...................................................................................................................................................................
Amphetamine (1100) ...................................................................................................................................................................................
Methamphetamine (1105) ...........................................................................................................................................................................
Methylphenidate (1724) ...............................................................................................................................................................................
Pentobarbital (2270) ....................................................................................................................................................................................
Phenylacetone (8501) .................................................................................................................................................................................
Hydromorphone (9150) ...............................................................................................................................................................................
Hydrocodone (9193) ....................................................................................................................................................................................
Methadone (9250) .......................................................................................................................................................................................
Methadone intermediate (9254) ..................................................................................................................................................................
Morphine (9300) ..........................................................................................................................................................................................
Sufentanil (9740) .........................................................................................................................................................................................
Fentanyl (9801) ...........................................................................................................................................................................................
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex North Brunswick, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cambrex North Brunswick,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22468 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
Dated: November 6, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22505 Filed 11–15–07; 8:45 am]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on PROD1PC66 with NOTICES
Road, Andover, Massachusetts 01810,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Morphine (9300), a
basic class of controlled substance listed
in schedule II.
The company plans to utilize small
quantities of the listed controlled
substance in the preparation of
analytical standards.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 15, 2008.
Manufacturer of Controlled
Substances; Notice of Application
BILLING CODE 4410–09–P
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on June 6, 2007,
Cambridge Isotope Lab, 50 Frontage
VerDate Aug<31>2005
21:48 Nov 15, 2007
Jkt 214001
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on October 16, 2007,
Cody Laboratories, 601 Yellowstone
Avenue, Cody, Wyoming 82414, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
Drug
Codeine (9050) .............................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Schedule
II
II
II
II
The company plans on manufacturing
the listed controlled substances in bulk
for sale to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than January 15, 2008.
E:\FR\FM\16NON1.SGM
16NON1
]]>Agencies
[Federal Register Volume 72, Number 221 (Friday, November 16, 2007)]
[Notices]
[Page 64677]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-22505]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on June 6, 2007, Cambridge
Isotope Lab, 50 Frontage Road, Andover, Massachusetts 01810, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of Morphine (9300), a basic class
of controlled substance listed in schedule II.
The company plans to utilize small quantities of the listed
controlled substance in the preparation of analytical standards.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Drug Enforcement
Administration, Office of Diversion Control, Federal Register
Representative (ODL), Washington, DC 20537, or any being sent via
express mail should be sent to Drug Enforcement Administration, Office
of Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than January 15, 2008.
Dated: November 6, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-22505 Filed 11-15-07; 8:45 am]
BILLING CODE 4410-09-P
